Overview
Disopyramide is a Class IA antiarrhythmic drug used in the management of cardiac rhythm disorders. It is a synthetic analogue of quinidine and is effective in treating both supraventricular and ventricular arrhythmias. Disopyramide works by blocking fast sodium channels in cardiac cells, thereby slowing impulse conduction and prolonging the action potential and refractory period. In addition to its antiarrhythmic action, it has significant anticholinergic effects and a negative inotropic effect, which require careful clinical monitoring.
Symptoms
Disopyramide itself does not cause symptoms unless adverse effects occur, but it is prescribed in patients with symptomatic arrhythmias such as palpitations, dizziness, syncope, chest discomfort, or breathlessness. Side effects may produce symptoms including dry mouth, blurred vision, constipation, urinary retention, nausea, vomiting, and hypotension. Cardiac-related adverse effects include worsening heart failure, QT prolongation, ventricular arrhythmias, and torsades de pointes. Hypoglycemia may also occur, especially in elderly patients or those with renal impairment.
Causes
Disopyramide is used to suppress abnormal cardiac rhythms caused by disordered electrical activity in the heart. It reduces automaticity and re-entry phenomena by slowing sodium influx into myocardial cells. The drug is indicated in ventricular tachycardia, ventricular fibrillation prevention, maintenance of sinus rhythm in atrial fibrillation or flutter, and symptomatic supraventricular tachycardias when other agents are ineffective or contraindicated. Toxicity occurs when plasma concentrations exceed the therapeutic range, often due to overdose, renal impairment, or drug interactions.
Risk Factors
Risk factors for adverse effects or toxicity include renal impairment, heart failure, conduction abnormalities, electrolyte imbalance, and advanced age. Patients with glaucoma, urinary retention, prostatic hypertrophy, or gastrointestinal obstruction are at higher risk due to anticholinergic effects. Concomitant use of other QT-prolonging drugs increases the risk of serious arrhythmias. Inadequate dose adjustment and lack of therapeutic drug monitoring also contribute to increased risk.
Prevention
Prevention of disopyramide-related complications relies on careful patient selection, dose adjustment, and therapeutic drug monitoring. Blood levels should be measured just before the next dose to ensure concentrations remain within the therapeutic range. Regular ECG monitoring helps detect QT prolongation and arrhythmias early. Dose modification in renal impairment, avoidance of interacting drugs, and close clinical follow-up reduce the risk of toxicity and improve treatment safety and effectiveness.
